Galmed Pharmaceuticals (GLMD) Receivables (2013 - 2024)

Galmed Pharmaceuticals' Receivables history runs 10 years deep, the most recent figure standing at $1.3 million for Q4 2024.

• In Q4 2024, Receivables rose 40.0% year-over-year to $1.3 million; the TTM figure through Dec 2024 stood at $1.3 million (up 40.0% YoY), while the FY2024 annual figure was $1.3 million, up 40.0% from the prior year.
• Receivables was $1.3 million for Q4 2024 at Galmed Pharmaceuticals, up from $960000.0 in the prior quarter.
• In the past five years, Receivables ranged from a high of $812.8 million in Q4 2020 to a low of $960000.0 in Q4 2023.
• Historically, Receivables has averaged $163.8 million across 5 years, with a median of $1.6 million in 2022.
• The sharpest annual moves came in 2020 and 2021: Receivables jumped 49042.2% in 2020, then slumped 99.72% in 2021.
• A 5-year view of Receivables shows it stood at $812.8 million in 2020, then plunged by 99.72% to $2.2 million in 2021, then retreated by 26.67% to $1.6 million in 2022, then tumbled by 41.82% to $960000.0 in 2023, then surged by 40.0% to $1.3 million in 2024.
• The last three Receivables figures came in at $1.3 million (Q4 2024), $960000.0 (Q4 2023), and $1.6 million (Q4 2022), per Business Quant data.